<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04808687</url>
  </required_header>
  <id_info>
    <org_study_id>TZ-PC02</org_study_id>
    <nct_id>NCT04808687</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Nab-Paclitaxel and S-1 in Resectable Pancreatic Cancer</brief_title>
  <official_title>Phase II Single-arm Trial of Nab-Paclitaxel and S-1 as Neoadjuvant Treatment of Patients With Resectable Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There were limited data for nab-paclitaxel and S-1 in pancreatic cancer. To explore the&#xD;
      efficacy and safety of neoadjuvant nab-paclitaxel combined with S-1 in patients with&#xD;
      resectable pancreatic cancer (stage II and partial stage III defined according to the&#xD;
      National Comprehensive Cancer Network definitions ), we designed this study. This study was a&#xD;
      single-arm single center prospective phase II clinical study. A total of 72 subjects who meet&#xD;
      the criteria will receive neoadjuvant chemotherapy of nab-paclitaxel and S-1 prior to&#xD;
      pancreatectomy. Response was reported according to the Response Evaluation Criteria in Solid&#xD;
      Tumors guidelines (RECIST, version 1.1) .The primary endpoint is objective response rate. The&#xD;
      secondary endpoints include R0/R1 resection rate, disease free survival, overall survival and&#xD;
      safety.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>From date of first dose until the date of first documented progression or date of death from any cause, whichever came first,assessed up to 24 months</time_frame>
    <description>Percentage of patients who achieve partial response (PR) or complete response(CR) based on Response Evaluation Criteria In Solid Tumors (RECIST1.1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>R0/R1 resection rate</measure>
    <time_frame>2 years</time_frame>
    <description>proportion of patients who achieved R0/R1 resection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>From date of randomization until the date of first documented progression or metastasis, assessed up to 12 months</time_frame>
    <description>The time between operation and the relapse or metastasis of tumors or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of randomization until the date of death from any cause or censored at the last day that the patient is documented to be alive, whichever came first, assessed up to 24 months</time_frame>
    <description>The time between randomization and death from any cause or lost to follow-up</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Pancreatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>nab-paclitaxel and S-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>neoadjuvant chemotherapy with Nab-paclitaxel and S-1, repeat every 21 days for 2-4 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab paclitaxel and S-1</intervention_name>
    <description>Nab-Paclitaxel: 125 mg/m2 d1, 8, during each 3-week cycle. S-1: Body surface area &lt; 1.25 m2, 40 mg bid; Body surface area ≥ 1.25 m2 &lt; 1.50 m2, 50 mg bid; Body surface area ≥1.5 m2, 60 mg bid, d1-14;during each 3-week cycle.</description>
    <arm_group_label>nab-paclitaxel and S-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed-consent form;&#xD;
&#xD;
          2. Treatment-naive PDAC with histological or cytological diagnosis;&#xD;
&#xD;
          3. Resectable pancreatic cancer stage II and partial stage III defined according to the&#xD;
             National Comprehensive Cancer Network definitions;&#xD;
&#xD;
          4. Age≥18 years old and ≤70 years old;&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;&#xD;
&#xD;
          6. BMI≥18.5 and NRS2002score&lt;3;&#xD;
&#xD;
          7. Expected survival over 3 months;&#xD;
&#xD;
          8. Spared organ function satisfying the following laboratory&#xD;
             data:leucocyte≥3.0x109/L,neutrophils≥1.5x109/L, hemoglobin≥ 9g/dL, platelets&#xD;
             ≥100x109/L, total bilirubin ≤ 1.5 ULN; AST and ALT≤ 2.5 ULN; serum creatinine≤1.5ULN;&#xD;
             PT and INR≤ 2.5 ULN;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe Impaired organ functions;&#xD;
&#xD;
          2. Patients who had surgeries, chemotherapy or other treatments before inclusion;&#xD;
&#xD;
          3. Pregnant women or lactating women;&#xD;
&#xD;
          4. Ineligible by the discretion of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jihui Hao</last_name>
    <phone>022-23340123-3077</phone>
    <email>tjzlyypc@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>30000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jihui Hao</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 17, 2021</study_first_submitted>
  <study_first_submitted_qc>March 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

